SLIT ABS: Study on Patients With Autoimmune Podocytopathy

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age0-99
SponsorMeyer Children's Hospital IRCCS

About this trial

Nephrotic syndrome is a kidney condition that mainly affects children and is characterized by high levels of protein in the urine, low levels of protein in the blood, and swelling. While many children respond well to steroid treatment, a large proportion experience relapses or become dependent on therapy. In some cases, the disease does not respond to standard treatments and may progress to chronic kidney disease.

Recent research suggests that, in addition to genetic factors, immune system mechanisms may play a key role in the development and progression of nephrotic syndrome. In particular, some patients produce autoantibodies against nephrin, an essential protein of the kidney filtration barrier. These autoantibodies may be associated with disease activity and treatment response.

The aim of this study is to investigate the presence of anti-nephrin autoantibodies in children with nephrotic syndrome and to better understand their role in disease mechanisms and clinical outcomes.The study will also explore the presence of other autoantibodies targeting components of the glomerular filtration barrier. The study will use advanced laboratory techniques, including blood tests and detailed analysis of kidney biopsy samples, to identify these antibodies and their relationship with kidney structure and function.

By integrating laboratory findings with clinical data, this study aims to improve the understanding of nephrotic syndrome and support the development of more personalized diagnostic and therapeutic strategies, with the goal of improving patient outcomes and reducing unnecessary or ineffective treatments.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Pediatric and adult patients with a diagnosis of podocytopathy

Patients with nephrotic syndrome and/or histological diagnosis of minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), collapsing glomerulopathy (CG), or diffuse mesangial sclerosis (DMS)

Both newly diagnosed (incident) patients and patients already under follow-up at participating centers

Availability of clinical data from medical records (including paper and/or electronic records, laboratory reports, and discharge summaries)

Disqualifiers

Refusal or inability of the patient, parents, or legal guardian to provide informed consent

Lack of sufficient clinical data or unavailable biological samples required for the study

Trial design

Design model

Single group

Treatments tested in this trial

  • Serum and renal tissue analysis

    Other intervention

    Analysis of serum and renal biopsy material collected as part of routine clinical care. Laboratory procedures include ELISA assays for the detection of anti-nephrin and/or others anti-slit antibodies and advanced imaging techniques, such as high-resolution confocal microscopy and STED microscopy, performed for research purposes

Treatment groups

50 Participants
are divided into 1 treatment group
Group A: Pediatric and adult patients with podocytopathiesExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Analysis of anti-nephrin antibody levels

Detection of circulating anti-nephrin antibodies in serum by ELISA and localization of antibody binding in renal biopsy tissue using high-resolution confocal and STED microscopy.

Time frame
From enrollment through 5 years of follow-up

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.